{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:43:17Z","timestamp":1777466597572,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["090532\/Z\/09\/Z"],"award-info":[{"award-number":["090532\/Z\/09\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["91070"],"award-info":[{"award-number":["91070"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is large individual variation in both clinical presentation and progression between Parkinson\u2019s disease patients. Generation of deeply and longitudinally phenotyped patient cohorts has enormous potential to identify disease subtypes for prognosis and therapeutic targeting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Replicating across three large Parkinson\u2019s cohorts (Oxford Discovery cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009842)\/Tracking UK Parkinson\u2019s study (<jats:italic>n<\/jats:italic>\u2009=\u20091807) and Parkinson\u2019s Progression Markers Initiative (<jats:italic>n<\/jats:italic>\u2009=\u2009472)) with clinical observational measures collected longitudinally over 5\u201310\u00a0years, we developed a Bayesian multiple phenotypes mixed model incorporating genetic relationships between individuals able to explain many diverse clinical measurements as a smaller number of continuous underlying factors (\u201cphenotypic axes\u201d).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When applied to disease severity at diagnosis, the most influential of three phenotypic axes \u201cAxis 1\u201d was characterised by severe non-tremor motor phenotype, anxiety and depression at diagnosis, accompanied by faster progression in cognitive function measures. Axis 1 was associated with increased genetic risk of Alzheimer\u2019s disease and reduced CSF A\u03b21-42 levels. As observed previously for Alzheimer\u2019s disease genetic risk, and in contrast to Parkinson\u2019s disease genetic risk, the loci influencing Axis 1 were associated with microglia-expressed genes implicating neuroinflammation. When applied to measures of disease progression for each individual, integration of Alzheimer\u2019s disease genetic loci haplotypes improved the accuracy of progression modelling, while integrating Parkinson\u2019s disease genetics did not.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We identify universal axes of Parkinson\u2019s disease phenotypic variation which reveal that Parkinson\u2019s patients with high concomitant genetic risk for Alzheimer\u2019s disease are more likely to present with severe motor and non-motor features at baseline and progress more rapidly to early dementia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13073-022-01132-9","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T13:05:12Z","timestamp":1668603912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Universal clinical Parkinson\u2019s disease axes identify a major influence of neuroinflammation"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8905-1052","authenticated-orcid":false,"given":"Cynthia","family":"Sandor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Millin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Kathrin","family":"Schalkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabila","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G.","family":"Grosset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele T.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/PL00007856","volume":"249","author":"T Foltynie","year":"2002","unstructured":"Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson\u2019s disease. J Neurol. 2002;249:138\u201345.","journal-title":"J Neurol"},{"key":"1132_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3233\/JPD-150662","volume":"5","author":"N Malek","year":"2015","unstructured":"Malek N, Swallow DM, Grosset KA, Lawton MA, Marrinan SL, Lehn AC, Bresner C, Bajaj N, Barker RA, Ben-Shlomo Y, et al. Tracking Parkinson\u2019s: Study Design and Baseline Patient Data. J Parkinsons Dis. 2015;5:947\u201359.","journal-title":"J Parkinsons Dis"},{"key":"1132_CR3","doi-asserted-by":"crossref","unstructured":"Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E,\nChowdhury S, et al. The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology 2011;95:629-35.","DOI":"10.1016\/j.pneurobio.2011.09.005"},{"key":"1132_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.parkreldis.2013.09.025","volume":"20","author":"K Szewczyk-Krolikowski","year":"2014","unstructured":"Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Wade-Martins R, Talbot K, Ben-Shlomo Y, Hu MT. The influence of age and gender on motor and non-motor features of early Parkinson\u2019s disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord. 2014;20:99\u2013105.","journal-title":"Parkinsonism Relat Disord"},{"key":"1132_CR5","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"SM Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain. 2017;140:1959\u201376.","journal-title":"Brain"},{"key":"1132_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JPD-140523","volume":"5","author":"M Lawton","year":"2015","unstructured":"Lawton M, Baig F, Rolinski M, Ruffman C, Nithi K, May MT, Ben-Shlomo Y, Hu MT. Parkinson\u2019s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) discovery cohort. J Parkinsons Dis. 2015;5:269\u201379.","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"1132_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","volume":"89","author":"M Lawton","year":"2018","unstructured":"Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, et al. Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry. 2018;89(12):1279\u201387.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1132_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.parkreldis.2016.04.026","volume":"28","author":"R Erro","year":"2016","unstructured":"Erro R, Picillo M, Vitale C, Palladino R, Amboni M, Moccia M, Pellecchia MT, Barone P. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism Relat Disord. 2016;28:137\u201340.","journal-title":"Parkinsonism Relat Disord"},{"key":"1132_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/ng.3513","volume":"48","author":"A Dahl","year":"2016","unstructured":"Dahl A, Iotchkova V, Baud A, Johansson A, Gyllensten U, Soranzo N, Mott R, Kranis A, Marchini J. A multiple-phenotype imputation method for genetic studies. Nat Genet. 2016;48:466\u201372.","journal-title":"Nat Genet"},{"key":"1132_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"Parkinson Progression Marker I","year":"2011","unstructured":"Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95:629\u201335.","journal-title":"Prog Neurobiol"},{"issue":"1605","key":"1132_CR11","first-page":"e1607","volume":"36","author":"MA Nalls","year":"2015","unstructured":"Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, Saad M, Jansen I, Guerreiro R, Lubbe S, et al. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging. 2015;36(1605):e1607-1612.","journal-title":"Neurobiol Aging"},{"key":"1132_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mds.26374","volume":"31","author":"MA Nalls","year":"2016","unstructured":"Nalls MA, Keller MF, Hernandez DG, Chen L, Stone DJ, Singleton AB, Parkinson\u2019s Progression Marker Initiative investigators. Baseline genetic associations in the Parkinson\u2019s Progression Markers Initiative (PPMI). Mov Disord. 2016;31:79\u201385.","journal-title":"Mov Disord"},{"key":"1132_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"NM Laird","year":"1982","unstructured":"Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963\u201374.","journal-title":"Biometrics"},{"key":"1132_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","volume":"5","author":"SK Holden","year":"2018","unstructured":"Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson\u2019s Progression Markers Initiative Cohort. Mov Disord Clin Pract. 2018;5:47\u201353.","journal-title":"Mov Disord Clin Pract"},{"key":"1132_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2125.2012.04192.x","volume":"74","author":"TC Vu","year":"2012","unstructured":"Vu TC, Nutt JG, Holford NH. Progression of motor and nonmotor features of Parkinson\u2019s disease and their response to treatment. Br J Clin Pharmacol. 2012;74:267\u201383.","journal-title":"Br J Clin Pharmacol"},{"key":"1132_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559\u201375.","journal-title":"Am J Hum Genet"},{"key":"1132_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41467-017-02317-2","volume":"9","author":"Z Zhu","year":"2018","unstructured":"Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, Robinson MR, McGrath JJ, Visscher PM, Wray NR, Yang J. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018;9:224.","journal-title":"Nat Commun"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1038\/s41467-020-17876-0","volume":"11","author":"D Agarwal","year":"2020","unstructured":"Agarwal D, Sandor C, Volpato V, Caffrey TM, Monzon-Sandoval J, Bowden R, Alegre-Abarrategui J, Wade-Martins R, Webber C. A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders. Nat Commun. 2020;11:4183.","journal-title":"Nat Commun"},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"e1004219","DOI":"10.1371\/journal.pcbi.1004219","volume":"11","author":"CA de Leeuw","year":"2015","unstructured":"de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.","journal-title":"PLoS Comput Biol"},{"key":"1132_CR20","first-page":"1","volume":"1695","author":"G Csardi","year":"2006","unstructured":"Csardi G, Nepusz T. The igraph software package for complex network research. InterJ Complex Syst. 2006;1695:1\u20139 http:\/\/igraph.sf.net.","journal-title":"InterJ Complex Syst"},{"key":"1132_CR21","doi-asserted-by":"crossref","unstructured":"Alexa A, Rahnenfuhrer J, Lengauer T. Improved scoring of functional groups from gene expression data\nby decorrelating GO graph structure. Bioinformatics 2006;22:1600-07.","DOI":"10.1093\/bioinformatics\/btl140"},{"key":"1132_CR22","unstructured":"Sayols S. Rrvgo: a Bioconductor package to reduce and visualize Gene Ontology terms. https:\/\/www.ssayolsgithubio\/rrvgo 2020."},{"key":"1132_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-020-2025-2","volume":"578","author":"DB Graham","year":"2020","unstructured":"Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020;578:527\u201339.","journal-title":"Nature"},{"key":"1132_CR24","doi-asserted-by":"publisher","first-page":"e1038","DOI":"10.1212\/WNL.0000000000005166","volume":"90","author":"DJ Irwin","year":"2018","unstructured":"Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, et al. CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology. 2018;90:e1038\u201346.","journal-title":"Neurology"},{"key":"1132_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13195-020-00696-1","volume":"12","author":"S Lehmann","year":"2020","unstructured":"Lehmann S, Dumurgier J, Ayrignac X, Marelli C, Alcolea D, Ormaechea JF, Thouvenot E, Delaby C, Hirtz C, Vialaret J, et al. Cerebrospinal fluid A beta 1\u201340 peptides increase in Alzheimer\u2019s disease and are highly correlated with phospho-tau in control individuals. Alzheimers Res Ther. 2020;12:123.","journal-title":"Alzheimers Res Ther"},{"key":"1132_CR26","doi-asserted-by":"publisher","first-page":"569777","DOI":"10.3389\/fnins.2020.569777","volume":"14","author":"R He","year":"2020","unstructured":"He R, Zhao Y, He Y, Zhou Y, Yang J, Zhou X, Zhu L, Zhou X, Liu Z, Xu Q, et al. Olfactory Dysfunction Predicts Disease Progression in Parkinson\u2019s Disease: A Longitudinal Study. Front Neurosci. 2020;14:569777.","journal-title":"Front Neurosci"},{"key":"1132_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0006-3223(93)90237-8","volume":"34","author":"MA Menza","year":"1993","unstructured":"Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson\u2019s disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993;34:465\u201370.","journal-title":"Biol Psychiatry"},{"key":"1132_CR28","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/124.11.2131","volume":"124","author":"A Berardelli","year":"2001","unstructured":"Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson\u2019s disease. Brain. 2001;124:2131\u201346.","journal-title":"Brain"},{"key":"1132_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/mds.26662","volume":"31","author":"M Delgado-Alvarado","year":"2016","unstructured":"Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jimenez-Urbieta H, Rodriguez-Oroz MC. Biomarkers for dementia and mild cognitive impairment in Parkinson\u2019s disease. Mov Disord. 2016;31:861\u201381.","journal-title":"Mov Disord"},{"key":"1132_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.nbd.2019.02.023","volume":"127","author":"M Shahid","year":"2019","unstructured":"Shahid M, Kim J, Leaver K, Hendershott T, Zhu D, Cholerton B, Henderson VW, Tian L, Poston KL. An increased rate of longitudinal cognitive decline is observed in Parkinson\u2019s disease patients with low CSF Ass42 and an APOE epsilon4 allele. Neurobiol Dis. 2019;127:278\u201386.","journal-title":"Neurobiol Dis"},{"key":"1132_CR31","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta Y, Parkkinen L, O\u2019Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, et al. Lewy- and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important? Brain. 2011;134:1493\u2013505.","journal-title":"Brain"},{"issue":"6395","key":"1132_CR32","doi-asserted-by":"publisher","first-page":"eaap8757","DOI":"10.1126\/science.aap8757","volume":"360","author":"C Brainstorm","year":"2018","unstructured":"Brainstorm C, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360(6395):eaap8757.","journal-title":"Science"},{"key":"1132_CR33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/mds.26578","volume":"31","author":"S Hall","year":"2016","unstructured":"Hall S, Surova Y, Ohrfelt A, Swedish Bio FS, Blennow K, Zetterberg H, Hansson O. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease. Mov Disord. 2016;31:898\u2013905.","journal-title":"Mov Disord"},{"key":"1132_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41588-020-0610-9","volume":"52","author":"J Bryois","year":"2020","unstructured":"Bryois J, Skene NG, Hansen TF, Kogelman LJA, Watson HJ, Liu Z, Eating Disorders Working Group of the Psychiatric Genomics Consortium, International Headache Genetics Consortium, Me Research Team, Brueggeman L, et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson\u2019s disease. Nat Genet. 2020;52:482\u201393.","journal-title":"Nat Genet"},{"key":"1132_CR35","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, et al. The Parkinson\u2019s progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5:1460\u201377.","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01132-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T13:07:42Z","timestamp":1668604062000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01132-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01132-9","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<i>Oxford Discovery cohort<\/i>: The clinical data were supplied by the OPDC study. This study was undertaken with the understanding and written consent of each subject, with the approval of the local NHS ethics committee (National Research Ethics Service (NRES) Committee South Central \u2013 Oxford A (Ref:16\/SC\/0108) and Oxford C (Ref:15\/SC\/0117); Berkshire Research Ethics Committee (Ref: 10\/H0505\/71)), and in compliance with national legislation and the Declaration of Helsinki.<i>Tracking UK<\/i>: The study is carried out in accordance with the Declaration of Helsinki and has been described in detail by Malek et al. [].<i>PPMI<\/i>: As described by Marek et al. [] This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines after approval of the local ethics committees of the participating sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.M. owns stocks and stock options in Regeneron Pharmaceuticals. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}